Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

McKesson Earnings Call: Key Takeaways

McKesson delivered a strong Q2 FY2027, beating internal expectations and raising full-year EPS guidance, driven by specialty distribution, GLP-1 volume, and strategic acquisitions in oncology and home infusion.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthPharma up 6%; Oncology/Multi-specialty up 24%; Prescription Tech up 10%.
Mgmt ConfidenceHigh confidence; raised full-year guidance based on strong first-half momentum.
Demand VisibilityStrong GLP-1 demand ($16B revenue); stable utilization in oncology networks.
Margin TrendsGross profit up 10% to $3.9B; operating profit up 13%.
Op. LeverageOperating expenses as percentage of gross profit improved 141 basis points.
Pricing PowerFairly compensated for distribution services; brand pricing decreases reduced revenue growth.
Vol vs PriceGrowth driven by higher prescription volumes, especially specialty and GLP-1 medications.
Segment GrowthOncology and Multi-specialty led growth; Med-Surgical solutions lagged with 5% growth.
New ClientsExtended CVS Health distribution relationship through June 2032.
Capex & DebtAcquired Precision Medicine Group for $2.25B; $1.4B investment in Option Care.
RegulatoryMonitoring 340B policy changes and potential January 2027 rebate model implementation.
CommentaryFocusing on community-based care and biopharma services to drive long-term value.
New LaunchesLaunched Family Forward ERG; introduced medical prior authorization capabilities.

Growth

Revenue grew 8% to $111B; adjusted EPS rose 18% to $11.68.

Outlook

Raised FY27 EPS guidance to $45.60-$46.40; targeting 13-16% long-term EPS growth.

Risks

Management was evasive on specific behavioral responses to potential 340B rebate model changes in 2027.

Source

The company's earnings call, NYSE: MCK, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Mckesson Corp: key numbers

Share price
$1,105.04Close, Nov 16
Market cap
$128B
Shares outstanding
115.46MLatest SEC cover page
Sector
Trade & Services
Industry
Wholesale-Drugs, Proprietaries & Druggists' SundriesSIC 5122

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Mckesson Corp

All →
12:52 PM ET Form 4
Insider Selling

Mckesson EVP, CIO and CTO Francisco Fraga Sells $717K of Stock

Francisco Fraga, EVP, CIO and CTO, sold 650 shares of Mckesson Corp at $1,102.96 a share, worth $717K in total on Nov 5, 2026. Shares held after the trade: 4,414 (-12.8%).

Value
$717K
Shares
650
Price
$1,102.96
Role
EVP, CIO and CTO
Holding change
-12.8%
Trade date
Nov 5, 2026
2:11 PM ET Form 4
Insider Selling

Mckesson EVP, CIO and CTO Francisco Fraga Sells $630K of Stock

Francisco Fraga, EVP, CIO and CTO, sold 600 shares of Mckesson Corp at $1,050.00 a share, worth $630K in total on Nov 4, 2026. Shares held after the trade: 5,064 (-10.6%).

Value
$630K
Shares
600
Price
$1,050.00
Role
EVP, CIO and CTO
Holding change
-10.6%
Trade date
Nov 4, 2026
5:30 PM ET 10-Q
Financial Results ▶ Call

Mckesson Q2 2026 Results: Net Income $1.22B, Up 9.7% YoY

For the three months ended September 30, 2026, McKesson reported revenues of $111.0 billion, a 7.6% increase year-over-year, and net income attributable to the corporation of $1.2 billion. The company's balance sheet shows a significant increase in total assets to $92.3 billion, primarily driven by higher cash and inventory levels, while stockholders' deficit widened to $4.0 billion.

Key figure
Net income $1.22B · +9.7% YoY
4:08 PM ET 8-K
Financial Results

Mckesson Financial Results

McKesson reported second quarter fiscal 2027 consolidated revenues of $111.0 billion, an 8% increase year-over-year, and raised its full-year adjusted EPS guidance. The results were driven by strong operational growth in the North American Pharmaceutical and Oncology & Multispecialty segments.

Term
Q2 2027

“McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise.”

Brian Tyler, chair and chief executive officer
4:40 PM ET Form 4
Insider Selling

Mckesson EVP, CIO and CTO Francisco Fraga Sells $797K of Stock

Francisco Fraga, EVP, CIO and CTO, sold 800 shares of Mckesson Corp at $995.80 a share, worth $797K in total on Oct 15, 2026. Shares held after the trade: 5,423 (-12.9%).

Value
$797K
Shares
800
Price
$995.80
Role
EVP, CIO and CTO
Holding change
-12.9%
Trade date
Oct 15, 2026
8:04 AM ET 8-K
M&A Deal

Mckesson Signs $5.8B M&A Deal with Option Care Health, Inc.

McKesson Corporation and Clayton, Dubilier & Rice (CD&R) have entered into a definitive agreement to acquire Option Care Health for $32.05 per share, representing a total enterprise value of approximately $5.8 billion. Upon closing, CD&R will hold a majority stake while McKesson will hold a minority interest in the home and alternate site infusion services provider. The deal aligns with McKesson's strategy to expand access to innovative therapies in lower-cost community and home settings.

Value
$5.8B
Counterparty
Option Care Health, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.